Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

A comprehensive study of effective responses as well as resistant responses to a kidney cancer anti-PD-1 therapy found ...

Combination treatment with nivolumab and cabozantinib provides long-term benefits over sunitinib in patients with advanced RCC, according to final results from the CheckMate 9ER trial.

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

The primary endpoint was progression-free survival (PFS; nivolumab/ipilimumab vs chemotherapy and nivolumab/ipilimumab vs nivolumab monotherapy). Findings showed the risk of disease progression or ...

In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.

Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior treatment, according to the TiNivo-2 study.

The FDA has accepted the sBLA for nivolumab (Opdivo) plus ipilimumab (Yervoy) as a potential first-line treatment for advanced MSI-H or dMMR CRC.